DBCO-(PEG)3-VC-PAB-MMAE
Based on 3 publication(s) in Google Scholar
DBCO-(PEG)3-VC-PAB-MMAE is a agent-linker conjugate for ADC. DBCO-(PEG)3-VC-PAB-MMAE is made by Monomethyl auristatin E (HY-15162) conjugats to DBCO-(PEG)3-vc-PAB linker. DBCO-(PEG)3-VC-PAB-MMAE can be used for the research of cancer. DBCO-(PEG)3-VC-PAB-MMAE is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 98.35%
- CAS 番号: 2754384-60-4
- 分子式: C86H124N12O18
- 分子量:1613.97
-
保管条件:
-20°C, stored under nitrogen
* The compound is unstable in solutions, freshly prepared is recommended.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
MedChemExpress（MCE）の使用を引用している文献 DBCO-(PEG)3-VC-PAB-MMAE
MoreDrug-Linker Conjugates for ADC アイソフォーム固有の製品をすべて表示
More
生物活性
|
Auristatin |
ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
化学情報
-
CAS 番号 2754384-60-4
-
性状 Solid
-
分子量 1613.97
-
分子式 C86H124N12O18
-
Color Off-white to pink
-
SMILES
CC[C@H](C)[C@@H]([C@@H](CC(N1[C@@H](CCC1)[C@@H]([C@@H](C)C(N[C@H](C)[C@@H](O)C2=CC=CC=C2)=O)OC)=O)OC)N(C([C@H](C(C)C)NC([C@H](C(C)C)N(C(OCC3=CC=C(NC([C@H](CCCNC(N)=O)NC([C@H](C(C)C)NC(CCOCCOCCOCCNC(CCC(N(C4)C5=C(C=CC=C5)C#CC6=C4C=CC=C6)=O)=O)=O)=O)=O)C=C3)=O)C)=O)=O)C
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
-20°C, stored under nitrogen
* The compound is unstable in solutions, freshly prepared is recommended.
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
2024 Oct 31;15(1):9406. PMID: 39477939 -
Nat Commun
Noncanonical amino acids as doubly bio-orthogonal handles for one-pot preparation of protein multiconjugates. [Abstract]2023 Feb 21;14(1):974. PMID: 36810592 -
溶剤 & 溶解度
DMSO : 60 mg/mL (37.18 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 1.5 mg/mL (0.93 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 1.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (15.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 1.5 mg/mL (0.93 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 1.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (15.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * The compound is unstable in solutions, freshly prepared is recommended.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (272 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
取扱説明書 (2659 KB)
参考文献
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.6196 mL | 3.0980 mL | 6.1959 mL | 15.4898 mL |
| 5 mM | 0.1239 mL | 0.6196 mL | 1.2392 mL | 3.0980 mL | |
| 10 mM | 0.0620 mL | 0.3098 mL | 0.6196 mL | 1.5490 mL | |
| 15 mM | 0.0413 mL | 0.2065 mL | 0.4131 mL | 1.0327 mL | |
| 20 mM | 0.0310 mL | 0.1549 mL | 0.3098 mL | 0.7745 mL | |
| 25 mM | 0.0248 mL | 0.1239 mL | 0.2478 mL | 0.6196 mL | |
| 30 mM | 0.0207 mL | 0.1033 mL | 0.2065 mL | 0.5163 mL |
DBCO-(PEG)3-VC-PAB-MMAE 関連分類
HY-111012 関連分類
Powered by Bioz